Lupin (NSE:LUPIN) Additional Paid-In Capital : ₹0 Mil(As of Mar. 2025)

View and export this data going back to 2001. Start your Free Trial

What is Lupin Additional Paid-In Capital?

Lupin's annual additional paid-in capital increased from Mar. 2023 (₹11,202 Mil) to Mar. 2024 (₹11,920 Mil) but then declined from Mar. 2024 (₹11,920 Mil) to Mar. 2025 (₹0 Mil).

Lupin Additional Paid-In Capital Historical Data

The historical data trend for Lupin's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Additional Paid-In Capital Chart

Lupin Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Additional Paid-In Capital

Get a 7-Day Free Trial

10,013.60

10,746.90

11,202.30

11,920.10

Lupin Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															11,920.10	-	-	-	-

Lupin Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Lupin Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Lupin's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lupin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

500257:India

Address

Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055

Website

https://www.lupin.com

Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines